NMMC Recruitment 2020: 5381 Vacancies Notified for ANM, Nurse, DEO and Other Posts, Apply Online @www.nmmc.gov.in – Jagran Josh

Navi Mumbai Municipal Corporation (NMMC) has invited applications for the post of MD Medicine, Medical Microbiologist, Intensivist, Jr Medical Officer (MBBS/ BAMS/ BHMS/ BUMS), Staff Nurse, Lab Technician, Pharmacist, ANM, Bedside Assistant, Data Entry Operator. Check Details Here

NMMC Recruitment 2020

NMMC Recruitment 2020: Navi Mumbai Municipal Corporation (NMMC) has invited applications for the post of MD Medicine, Medical Microbiologist, Intensivist, Jr Medical Officer (MBBS/ BAMS/ BHMS/ BUMS), Staff Nurse, Lab Technician, Pharmacist, ANM, Bedside Assistant, Data Entry Operator. Eligible and interested candidates can apply for Navi Mumbai Mahanagarpalika Bharti 2020 through Google Form Link on or before 20 July 2020.

NMMC Important Dates

Last Date of Application - 20 July 2020

NMMC Vacancy Details

Total Posts - 5381

Salary:

Eligibility Criteria for ANM, Nurse, DEO and Other Posts

Educational Qualification:

For more information, check detailed notification link

How to Apply for NMMC Recruitment 2020 ?

Eligible candidates can apply online for the posts through Google Link on or before 20 July 2020.

NMMC Recruitment Notification PDF

Online Application Link

See the rest here:

NMMC Recruitment 2020: 5381 Vacancies Notified for ANM, Nurse, DEO and Other Posts, Apply Online @www.nmmc.gov.in - Jagran Josh

EAU 2020: ProPSMA Study: A Prospective Randomised Multi-Centre Study of PSMA-PET/CT Imaging for Staging High Risk Prostate Cancer Prior to…

(UroToday.com)As part of the Game-Changing Session 1 plenary presentation at the 2020 European Association of Urology (EAU) Virtual Annual Meeting, Dr. Michael Hofman presented results of the proPSMA study which was recently published in the Lancet.1

For patients with intermediate and high-risk localized prostate cancer who are being considered for local therapy, pre-treatment staging is important to exclude or at least characterize the burden of metastatic disease. To date, bone scintigraphy and abdominopelvic computed tomography have been utilized even though there are known issues related to poor sensitivity. Prostate-specific membrane antigen (PSMA) based imaging using PET/CT fusion has been increasingly used for patients with recurrent prostate cancer. In the proPSMA study, Dr. Hofman and colleagues set to determine the role of PSMA PET/CT in pre-treatment staging.

They performed a multi-center, two-arm randomized controlled trial among men with histologically confirmed prostate cancer who were being considered for curative intent radical prostatectomy or radiotherapy. To be eligible for inclusion, men must have had at least one high-risk factor including prostate-specific antigen (PSA) greater than or equal to 20 ng/mL, ISUP grade group 3-5, or clinical stage T3 or greater. Patients who had undergoing staging investigations (apart from prostate MRI) within eight weeks prior to randomization were excluded.

Following enrollment, patients were randomly assigned in a 1:1 ratio to either conventional imaging performed using bone scan and CT or PSMA PET/CT. Randomization was stratified according to the center. Patients who were randomized to conventional imaging underwent an abdominopelvic CT scan with contrast as well as a technetium-99m bone scan with SPECT CT of chest, abdomen, and pelvic in keeping with the standard of care. These investigations were assessed in aggregate to determine the presence of findings of interest. For patients randomized to PET/CT, gallium-68 PSMA-11 PET/CT was performed. In patients who had fewer than three unequivocal sites of metastasis, cross-over imaging for confirmation was performed within 14 days. Confirmatory testing following imaging was performed at the discretion of the treating physician and included biopsy confirmation.

The primary study outcome was the accuracy of first-line diagnostic imaging for the identification of either pelvic nodal or distant metastatic disease. Accuracy was assessed using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve. The reference standard was a composite panel of histopathology, imaging, clinical, and biochemical characteristics.

The authors estimated a sample size of 300 total patients to achieve a power of 85% to distinguish between conventional imaging with an AUC of 0.65 (sensitivity 0.65 and specificity 0.65) and PET-CT with an AUC of 0.90 (sensitivity 0.90 and specificity 0.90) assuming an event rate of 25% of patients harboring nodal or distant metastatic disease and a two-sided type I error of 0.10.

Between 20017 and 2018, the authors randomly assigned 302 patients of whom 300 received assigned first-line imaging. In keeping with the prostate cancer population, the median age was 68 years, 293 men had ISUP grade 3 or higher, 65 had PSA 20 ng/mL or higher, and 82 had clinical stage T3 or T4. 96% (146) of men assigned to conventional imaging underwent subsequent second-line PSMA PET-CT.

Assessment of the reference standard was possible in 295 (98%) of men, including 87 of whom had evidence of nodal or distant metastasis. Of these, hard criteria were used to define disease in 20 men.

In the primary outcome assessment, PSMA PET-CT had a 27% absolute greater AUC for accuracy compared to conventional imaging (95% confidence interval [CI] 23-31): 92% (95% CI 88-95%) vs. 65% (60-69%). Conventional imaging had both a lower sensitivity (38% vs. 85%) and also a lower specificity (91% vs. 98%).

The authors performed a sensitivity analysis in which all lesions rated as equivocal were considered positive. This changed the results only marginally with an absolute difference of 28% (95% CI 23-33%). These results were also consistent in subgroups of patients with pelvic nodal disease and those with distant metastasis. Further posthoc subgroup analysis showed an incremental benefit for PSMA PET-CT in men with Gleason Grade Group (GGG) 4-5 disease, those with GGG less than or equal to 3, and those with a PSA of 20 ng/mL or greater.

Further, equivocal findings were more common in men undergoing conventional imaging (23%) compared to those undergoing PSMA PET-CT (7%).

Prior to treatment, the results of conventional imaging studies resulted in treatment change for 23 men (15%, 95% CI 10-22) while the results of PSMA PET-CT resulted in treatment change for 41 (28%, 95% confidence interval 21-36). These changes included both a transition from curative intent to palliative intent treatment in 20 patients (14%) and also a change in treatment approach in 22 (14%). These data demonstrate the clinical utility of utilizing PSMA PET-CT in this clinical space.

Further, conventional imaging was associated with a higher radiation dose (19.2 mSv compared to 8.4 mSv; absolute difference 10.9 mSv, 95% CI 9.8-12.0 mSv0. PSMA PET-CT was not associated with any adverse events and reporter agreement was high for both nodal (kappa 0.87, 95% CI 0.81-0.94) and distant metastatic disease (kappa 0.88, 95% CI 0.94-0.92).

Presented by:Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, Professor of Molecular Imaging, The University of Melbourne, Nuclear Medicine Physician, Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia

Written by:Christopher J.D. Wallis, MD, PhD, Urologic Oncology Fellow, Vanderbilt University Medical Center, Twitter: @WallisCJDat the Virtual 2020 EAU Annual Meeting #EAU20, July 17-19, 2020

Reference:

1.Hofman, Michael S., Nathan Lawrentschuk, Roslyn J. Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford et al. "Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study."The Lancet(2020).

Related Content:Watch:PSMA PET/CT Imaging for Staging High-risk Prostate Cancer Prior to Curative-intent Surgery or Radiotherapy (proPSMA) - Michael Hofman and Declan Murphy

Read more from the original source:

EAU 2020: ProPSMA Study: A Prospective Randomised Multi-Centre Study of PSMA-PET/CT Imaging for Staging High Risk Prostate Cancer Prior to...

Most countries face nuclear imaging supply issues, and COVID-19 has only exacerbated the problem – Health Imaging

Scott and colleagues received responses from key society contacts in the International Atomic Energy Agency database. For North America, Latin America and Australia the data represented 91.3% to 100.0% of nuclear medicine camera sites. Half of locations in Africa were represented, but European responses were low, which likely affected the survey results.

In addition to Mo-99/Tc-99 supply issues, respondents noted problems reliably obtaining cold kits, which are used to simplify radiopharmaceutical production and enable consistency across varying sites. More than half of the 33 radiopharmaceutical kit manufacturers provide to only a single country and eight provide kits to two countries.

Additionally, all countries said they lack trained and qualified staff, including clinicians, radiochemists and physicists, to perform tasks such as quality assurance and proper labeling. This also hampered their ability to offer complex procedures, Scott et al. noted.

Issues also extended into specific radiopharmaceuticals, with only 28 countries indicating they offered PET services. Low and low-middle income countries had the fewest number of sites. The most widely used agent is 18F-FDG, but non-FDG tracers were limited in most countries due to high cost, no access to a cyclotron, and regulatory restrictions, among other reasons.

Most respondents also do not have access to therapeutic tracers, such as 123I, 123I-MIBG and 131I-MIBG, because of costs and supply or distributor issues.

The data obtained in this survey project clearly shows that all countries have issues of radiopharmaceutical access and availability, although the capability to address these issues varies according to the size of the country, funding and nuclear medicine infrastructure, the group noted.

Read this article:

Most countries face nuclear imaging supply issues, and COVID-19 has only exacerbated the problem - Health Imaging

Muscle and serum myostatin expression in type 1 diabetes. – Physician’s Weekly

Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle-wasting diseases, has not been reported in humans with T1D but has been demonstrated to be elevated in preclinical diabetes models. Thus, the purpose of this study was to determine if there is an elevated expression of myostatin in the serum and skeletal muscle of persons with T1D compared to controls. Secondarily, we aimed to explore relationships between myostatin expression and clinically important metrics (e.g., HbA , strength, lean mass) in women and men with (N=31)/without T1D (N=24) between 18 and 72years old. Body composition, baseline strength, blood sample and vastus lateralis muscle biopsy were evaluated. Serum, but not muscle, myostatin expression was significantly elevated in those with T1D versus controls, and to a greater degree in T1D women than T1D men. Serum myostatin levels were not significantly associated with HbA nor disease duration. A significant correlation between serum myostatin expression and maximal voluntary contraction (MVC) and body fat mass was demonstrated in control subjects, but these correlations did not reach significance in those with T1D (MVC: R= 0.64 controls vs. R= 0.37 T1D; Body fat: R=-0.52 controls/R=-0.02 T1D). Collectively, serum myostatin was correlated with lean mass (R= 0.45), and while this trend was noted in both groups separately, neither reached statistical significance (R= 0.47 controls/R= 0.33 T1D). Overall, while those with T1D exhibited elevated serum myostatin levels (particularly females) myostatin expression was not correlated with clinically relevant metrics despite some of these relationships existing in controls (e.g., lean/fat mass). Future studies will be needed to fully understand the mechanisms underlying increased myostatin in T1D, with relationships to insulin dosing being particularly important to elucidate. 2020 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

PubMed

Original post:

Muscle and serum myostatin expression in type 1 diabetes. - Physician's Weekly

Does TB vaccine protect from coronavirus? Heres what experts say – Business Today

A tuberculosis vaccine may help reduce the risk of death from novel coronavirus, according to two peer-reviewed studies released last week. According to the authors of the study, developing countries, where TB vaccine was given on higher rates, have lower-than-expected COVID-19 death rates.

One of the studies led by Indian researchers from the Jawaharlal Nehru University (JNU) stated that the quality of protection from COVID-19 dependent upon the TB vaccine strain, the Hindustan Times reported. The widely-used TB vaccine-Bacillus Calmette-Guerin (BCG) has six major strains Pasteur, Danish, Glaxo 1077 (derived from the Danish strain), Tokyo, Russia, and Moreau.

Gobardhan Das, chairperson, Centre for Molecular Medicine at JNU said that BCG has offered some degree of protection against COVID-19, but all the countries (that give BCG vaccines to their children) did not do equally well. Das added that BCG Mix, BCG Pastuer, and BCG Tokyo do better compared to others, such as BCG Russia and BCG Danish. In India, BCG Mix vaccine is used.

The peer-reviewed study was published in Cell Death and Disease.

In India, BCG vaccination of children started in 1949. In 2019, at least 97 per cent of the 2.6 crore children received the TB vaccine. The vaccine in children prevents a simple TB from turning into a systemic and affecting the brain and other organs. However, it doesn't offer protection from adult pulmonary TB, which has led to several countries discontinuing its use. Das said that BCG also had protective effects against leprosy, buruli ulcer, bladder cancer, type-1 diabetes and several other diseases.

The World Health Organisation (WHO) in April said that there was no evidence that BCG protected people against coronavirus.

According to the daily, many clinicians and epidemiologists were also unconvinced about the findings. Dr Krishnan Chhugh, director of pediatrics at Fortis Memorial Research Institute said that it was highly unlikely that the protection would last till adulthood. "The vaccine just prevents simple TB from becoming systemic and affecting the brain and other organs," says Chugh.

Also, epidemiologists are wary that most countries with high BCG vaccination rates, like India and Brazil, are not testing enough. Prof Madhukar Pai, Director, McGill University, Montreal, said that it was dangerous to make conclusions in such a dynamic situation. Pai tweeted, "We simply cannot act on these correlations and must wait for randomised trials on BCG and COVID-19".

Also read: Over 90 doctors on COVID-19 duty lost their lives so far, says IMA

Also read: WHO chief Tedros condemns 'mixed messages' on coronavirus pandemic from world leaders

Read this article:

Does TB vaccine protect from coronavirus? Heres what experts say - Business Today

Italian Institute Revokes Appointment of Cancer Researcher – The Scientist

The Veneto Institute of Molecular Medicine in Padua, Italy, has revoked its nomination of cancer researcher Pier Paolo Pandolfi as scientific director following allegations of sexual harassment and scientific misconduct against him.

Pandolfi, who admits one instance of harassment but denies any research wrongdoing, was nominated as the scientific director for the Veneto Institute (VIMM) on May 20. The move prompted protests by members of the institutions scientific advisory board, who subsequently resigned en masse when the nomination was confirmed on June 25, with members saying they had not been properly consulted, Nature reports.

There should have been more investigation before making the appointment, board member Aaron Ciechanover, a biochemist and Nobel Prize winner based at Technion Israel Institute of Technology, tells Nature.

The sexual harassment allegations that Pandolfi admits to concern a Harvard postdoc, who tells Nature that Pandolfi organized too many one-to-one meetings where he talked about his feelings for me and that he frequently sent her personal emails. It was embarrassing, horrible and I was not able to work, says the postdoc, whom Nature has kept anonymous, adding that she was transferred to a different research group in early 2019.

Pandolfi left Harvard in December last year, following an investigation into this behavior. He denied in an interview with the Italian newspaper Corriere della Sera on June 27 that this was the reason for his departure. In the interview, Pandolfi acknowledged that he had behaved inappropriately toward the postdoc, but said that the incident was isolated and that he was sorry.

The other allegations concern problems with images in papers published by Pandolfi. Enrico Bucci, a science-integrity expert in Samone, Italy, found problems in 13 papers that list Pandolfi as a coauthor, Naturereports.

In a statement announcing the revocation of its nomination on June 30, the institute stated that it had not been informed of the incidents at Harvard University, Corriere della Serareports in a subsequent article. The statement added that VIMM would be looking for a new scientific director as soon as possible.

In May, Pandolfi had taken on a part-time position on the faculty of the Desert Research Institute in Nevada. According to Nature, he resigned from that position on June 30 following VIMMs decision.

Read the original here:

Italian Institute Revokes Appointment of Cancer Researcher - The Scientist

Kainomyx Announces the Launch of Its Programs Focused on Malaria and Other Parasitic Diseases – BioSpace

SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Kainomyx, Inc., founded in September 2019 and financed with $7.5 Million in May 2020, today announced launch of its programs to address malaria and other parasitic diseases. Leveraging their expertise in the biotech world and cytoskeletal biology, Kainomyx was founded by five current and former Stanford scientists who are experts in the biology, biochemistry and biophysics of the cytoskeletal proteins of cells - James Spudich, PhD, Annamma Spudich, PhD, Darshan Trivedi, PhD, Suman Nag, PhD and Kathleen Ruppel, MD, PhD. Together, they share a conviction that there is a critical need for new therapeutic innovations for treating malaria, leishmaniasis, and other parasitic diseases. Existing efforts to develop therapeutic agents for treatment of malaria and other parasitic diseases often start with screening for small molecule inhibitors of invasion of the parasites into their host cells. While an important approach, the likelihood of success in drug development correlates well with the understanding of the mechanism of action of the target, said James Spudich, President and CEO of the new company and former Chair of the Department of Biochemistry at Stanford University School of Medicine (and recipient of the Lasker Award for his work on Molecular Motors). Our approach is to develop small molecule therapeutics against target proteins that we have studied for decades and meet six essential characteristics they are vital components of parasite function, mechanistically well understood, essential at multiple stages of the parasite life cycle, highly druggable, less likely to be subject to resistance, and can be targeted with high specificity.

About Parasite Diseases

Parasitic infections cause devastating health and economic consequences world-wide and remain some of the most significant public health challenges globally. Until recently, parasitic diseases were considered to be confined to non-western nations. However, world-wide travel and on-going alterations in climatic conditions have made boundaries more porous, and diseases once restricted to specific areas are becoming global.

There is an urgent need for novel therapies to treat parasitic diseases. The mechanisms of action of current therapeutics for malaria, for example, are generally not well understood, and resistance is now developing against Artemisinin-based Combination Therapy (ACT), the current primary therapy for malaria. Thus, novel targets for malaria drug development are in great need.

Kainomyx Focus

Kainomyx is focusing on targeting the cytoskeletal proteins of parasites to develop small molecule therapeutics targeted at malaria and other parasitic diseases. The cytoskeleton, a term coined by Spudich and his colleagues in 1976 from their work on mammalian cells, is a multicomponent system of molecular motors, tracks along which they move, and associated proteins involved in their dynamic organization within cells. The cytoskeleton is essential for multiple pivotal cell functions and is the structural organizational framework for all cells. Over the last fifty years, Spudich and his team, first at the University of California, San Francisco, and then at Stanford University, have focused their efforts on understanding the molecular details of the functions of the cytoskeleton of a variety of cell types.

In addition to his years of experience in academia, Spudich co-founded Cytokinetics, Inc. in 1998 and MyoKardia, Inc. in 2012. Cytokinetics is focused to the discovery and development of novel mechanism modulators of cytoskeletal biology with focus to muscle biology and pharmacology.MyoKardia is focused to the discovery and development of new treatments for genetic diseases of the heart.

At Kainomyx, Spudich and his colleagues are leveraging their academic and biotech expertise to treat one of the most devastating diseases of all time, malaria, which kills more than 450,000 people every year, and the majority of deaths are children under the age of 10. The challenge is to develop novel therapeutic approaches to treat malaria but also to develop sensitive, accurate, easy to execute diagnostic tests to identify asymptomatic carriers who contribute to the transmission of malaria parasites. Kainomyx is pursuing the necessary targets to achieve these goals.

Cytokinetics Helps Jumpstart Kainomyxs Research Programs

Cytokinetics is facilitating Kainomyxs programs on treatment of malaria and other parasitic diseases by assigning and transferring to Kainomyx all of Cytokinetics rights, title and interest in and to several existing compounds that act as modulators of the parasite cytoskeletal system. Kainomyx will also be incubating at Cytokinetics, the first company devoted to developing small molecule therapeutics targeting the molecular motor-based machinery of cells. Spudich said, I am pleased to be once again working in close proximity to my colleagues at Cytokinetics, a company I co-founded in 1998 and where I worked for the first year of Cytokinetics research program while on leave of absence from Stanford University.

Financing of Kainomyx

Initial funding for Kainomyx of $7.5M came in May of this year. William J. Rutter, PhD, the primary investor, was co-Founder of the early biotech company Chiron and multiple additional companies. Rutter is Founder, Chairman and CEO of Synergenics, LLC, which controls a consortium of companies with different but complementary approaches to diagnosis, prevention and treatment on a worldwide basis. Rutter, commenting on Kainomyx, said, There is a dire need for new developments for successfully treating malaria and a series of other parasitic diseases, which have plagued humans for centuries. I am very impressed with Kainomyxs strategies to have a major impact in this area. Current drugs have been only partially successful and have not eliminated the spread of the disease. Several of the large pharma companies have had programs for these diseases, but to my knowledge, only occasionally have yielded any success. More recently, several small biotech startups have focused on these diseases with varying strategies, but none have been successful. In contrast, Kainomyx has a strategic approach which can be focused on several diseases in this area by targeting mechanistically well-understood cytoskeletal elements that are crucial for vitality of these organisms. Jim Spudich and colleagues have been the leaders in elucidating the fundamental mechanisms by which these cytoskeletal elements work. There is no better team to lead this innovative new strategy, which provides an unusual investment opportunity to make an impact on human life.

Additional funding was provided by Open Philanthropy and James and Annamma Spudich.

Board of Directors, Kainomyx

Kainomyxs Board of Directors is Chaired by Dr. William J. Rutter. He is joined by Dirk Thye, MD, serial entrepreneur who has led multiple small and medium sized companies in successful product development and is currently Executive Chairman at Geom Therapeutics. The third Board member is Amit L. Mehta, PhD, a Life Science Research Foundation Fellow at Bell Labs and Stanford University in his early career, later an Associate Partner at McKinsey and Company, followed by Managing Director at Morgan Stanley and Goldman Sachs, and is currently Managing Director at J.P. Morgan.

Contact:

KainoymxAnnamma Spudich, PhDCo-Founder(650) 223-4954

More here:

Kainomyx Announces the Launch of Its Programs Focused on Malaria and Other Parasitic Diseases - BioSpace

IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthca – PharmiWeb.com

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Read more:

IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthca - PharmiWeb.com

US death toll starts to rise again, reversing three-month fall – Telegraph.co.uk

In terms of recorded cases, the United States has become the worst-affected country, with more than 3.1 million diagnosed Covid 19 cases and at least 133,291 deaths since the crisis beganin January.

The US Centers for Disease Control (CDC) predicts the nations coronavirus death toll will rise to between 140,000 to 160,000 deaths by August.

The trend will likely continue unless social distancing can be effectively reinstituted across the south and mid-west of the country.

As predicted, a month from the case surge started, we are moving to a higher death rate in the US, Dr Eric Topol, a Professor of Molecular Medicine at The Scripps Research Institute in La Jolla, California, tweeted.

I think the shift to younger patients and better treatments will lead to a flatter slope compared with April. But thwarting the surge could have prevented this altogether.

See the article here:

US death toll starts to rise again, reversing three-month fall - Telegraph.co.uk

Latest Innovation in Bioinformatics Service Market 2019-2025| Emerging Technologies, Share, Competitive, Regional, Top Companies- QIAGEN, CD Genomics,…

Global Bioinformatics Service Market report 2020 contains the information regarding market share, company performances (stocks), comprehensive analysis, consumer perspective, historical analysis, statistics, market forecast 2020 to 2025 in terms of revenue, volume, growth rate, and CAGR. This report target Bioinformatics Service volume and value at a global level, regional and company level. Bioinformatics Service report target market product specifications, current competitive players in Bioinformatics Service market and the markt revenue with profitability.

Get Sample Copy of This Report @ https://www.orianresearch.com/request-sample/1376570

Bioinformatics Service Market report 2020 is Business Professionals analysis which is based on past information and future opportunities in the global market. The Bioinformatics Service report consists of valuation of enterprise key producers, evaluation of advertising trader or distributor, development trends, production analysis, intake volume and price analysis, sales and market popularity.

This Bioinformatics Service market research report helps provide insights into innovations, opportunities and new development in the Bioinformatics Service and its connected industries.

The regions which have been studied in depth are North America, Europe, Asia Pacific, Middle East & Africa and Latin America. This helps gain better idea about the spread of this particular market in respective regions.

Bioinformatics Service Market Segmentation Analysis: By Market Players: Agilent Technologies QIAGEN CD Genomics Thermo Fisher Scientific Illumina Strand Life Sciences BGI Group DNANEXUS Biomax Informatics Gene Codes Creative-Biolabs FIOS Genomics Gene Code DNASTAR

The report delivers a comprehensive overview of the crucial elements of the Bioinformatics Service market and elements such as drivers, restraints, current trends of the past and present times, supervisory scenario, and technological growth. A thorough analysis of these elements has been accepted for defining the future growth prospects of the global Bioinformatics Service market.

A brief synopsis of the Bioinformatics Service industry supplied in the report consists of enterprise information evaluation, enterprise policy evaluation, definitions, specifications, applications, and classifications.

Order a Copy of This Report @ https://www.orianresearch.com/checkout/1376570

Bioinformatics Service Market is segmented based on product type, applications along with geographical fragmentation including the North America, Europe and Asia-Pacific, South America, Middle East and Africa.This Bioinformatics Service report deals with major aspects including region-wise manufacture capacity, price, demand, supply chain, profit and loss, row material parameters and specifications, consumption, export and import details, growth rate, and Bioinformatics Service market structure.

Market Segment by Type, covers Drug Development Gene Therapy Molecular Medicine Veterinary Science Others

Market Segment by Applications, can be divided into Academics and Research Centers Pharmaceutical and Biotechnology Industries Forensics Laboratories OthersBioinformatics Service Market Study Objectives Are:

Examine and research the global Bioinformatics Service status and future forecast, involving, production, revenue, consumption, historical and forecast. Report presents the key Bioinformatics Service manufacturers, production, revenue, market share, SWOT analysis, and development plans in the next few years.

Bioinformatics Service Report Segments the breakdown data by regions, type, manufacturers, and applications.

Analyze the global and key regions Bioinformatics Service market potential and advantage, opportunity and challenge, restraints and risks.

Bioinformatics Service Report Identify significant trends, drivers, influence factors in global and regions.

Strategically analyze each submarket with respect to individual growth trend and their contribution to the Bioinformatics Service market.

Report Analyze competitively developments such as expansions, agreements, new product launches, and acquisitions in the Bioinformatics Service market.

Finally, Bioinformatics Service Market report is the believable source for gaining the market research that will exponentially accelerate your business. Additionally, it Presents new task SWOT examination, speculation attainability investigation, and venture return investigation.

Customization of This report: Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Contact us ([emailprotected]) and let us know about your challenges and our trusted advisors will connect with you. We will happy to assist you.

Contact Us:

Ruwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS +1 (415) 830-3727 | UK +44 020 8144-71-27

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products.

Read this article:

Latest Innovation in Bioinformatics Service Market 2019-2025| Emerging Technologies, Share, Competitive, Regional, Top Companies- QIAGEN, CD Genomics,...

Global Bioinformatics Market To See Booming Worldwide | Top Key Players- Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc. – Daily Research…

A recent report published by QMI on bioinformatics market is a detailed assessment of the most important market dynamics. After carrying out thorough research on the market of bioinformatics historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for bioinformatics during the forecast period. It can enable manufacturers of bioinformatics to change their production and marketing strategies in order to envisage maximum growth. The market report on bioinformatics offers detailed information for stakeholders in the most comprehensive way on the current and future growth prospects of the demand for bioinformatics market.

To Request Sample Premium Reports:https://www.quincemarketinsights.com/request-sample-60484?utm_source=SSK&utm_medium=DRA&utm_campaign=SSK

This report provides comprehensive taxonomy and the description of industry-related products, applications and end-user channels for the bioinformatics market. This report also provides insight into market concepts for phase. This contains opportunity analysis which provides information on the most relevant macroeconomic and microeconomic factors affecting market revenues and estimates for the phase. The market background is discussed in the report which sheds a light on the key drivers, threats, patterns and opportunities in the demand for bioinformatics market. A global overview has been presented for bioinformatics products, supply chain analysis and hazard analysis, which is expected to help readers identify the key factors that support the growth of the demand for bioinformatics market. The report discusses the regulatory scenario affecting approvals for the products, across leading regions. It also provides information on the demand of the bioinformatics market adopted in leading countries. It includes a specific list of retailers and manufacturers dealing in bioinformatics market. Readers will also be able to find regional developments and regulations that impact market growth. Significant growth prospects are given for countries which also include key regional developments and factors that influence the growth of the demand for bioinformatics market. The report studies business patterns of top companys like- fujifilm holdings corporation, analogic corporation, siemens healthcare, esaote s.p.a, toshiba medical systems corporation, ge healthcare, philips healthcare, hitachi medical corporation, and mindray medical international ltd

Bioinformatics market growth is expected to gain high momentum during the forecast period due to increasing demand for imaging devices for diagnostics applications. An ceiling-mounted surgical lights is a medical imaging device, which uses high-frequency waves to visualize the internal organs of the body such as blood vessels, kidney, liver, human foetus, heart, etc. This market is gaining momentum, owing to the increase in the number of hospitals and adoption of technologically advanced devices, which can serve the purpose for both diagnostics and therapeutics. Moreover, the cumulative prevalence of cancer is driving the demand for early detections and minimization of expenses. According to the Cancer Research Institute (CRI), there were approximately 17 million new cases of cancer globally, as of 2017, which is also fuelling the demand for ultrasound devices.

Segment Analysis

The bed head multifunctional belt market has been segmented by type (platforms, tools, services), by applications (preventive medicine, molecular medicine, gene therapy drug development). Based on portability, the market can be divided into trolley/cart and compact/handheld. Based on application, the market has been divided into radiology, gynaecology, urology, cardiology, orthopaedic/musculoskeletal, and others. Owing to the growing incidences of stem cell-based injuries and the demand for high-quality diagnostic procedures, the radiology segment is expected to lead. The market has been studied for North America, Western Europe, Eastern Europe, Asia Pacific, and Rest of the World.

Key Factors Impacting Market Growth:

Regional Outlook:

North America, Western Europe, and Asia Pacific by region are estimated to dominate the ultrasound market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favourable for the growth of the healthcare infrastructure in these regions. North America and Western Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for ultrasound market during the forecast period.

The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for ultrasound market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for ultrasound market in the region. Other regions including Middle East, Eastern Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for ultrasound during the forecast period.

Speak To Analyst before Buying This: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-60484?utm_source=SSK&utm_medium=DRA&utm_campaign=SSK

Market Segmentation:

By Type Platforms Tools Services

By Applications Preventive Medicine Molecular Medicine Gene Therapy Drug Development

By Region:

Major Companies:Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc., CLC bio A/S, Agilent Technologies Inc., GenoLogics Life Sciences Software, Inc., Life Technologies Corporation, Illumina, Inc.

Reasons to Buy This Report:

Customization:

We provide customization of the study to meet specific requirements:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: US +1 208 405 2835 / UK +44 121 364 6144 / APAC +91 706 672 4848

Email:[emailprotected]

Web: http://www.quincemarketinsights.com

View original post here:

Global Bioinformatics Market To See Booming Worldwide | Top Key Players- Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc. - Daily Research...

Postdoctoral Fellow, Department of Chemistry job with THE UNIVERSITY OF HONG KONG | 213493 – Times Higher Education (THE)

Work type: Full-timeDepartment: Department of Chemistry (25200)Categories: Academic-related Staff

Applications are invited for appointment as Post-doctoral Fellow (several posts) in the Department of Chemistry (Ref.: 500595), to commence as soon as possible for one year, with the possibility of renewal.

Applicants should possess a Ph.D. degree in Chemistry, Biomedical Science or a related discipline from a local university focusing on the following four research programs: (i) Synthetic Chemistry; (ii) Chemical Biology of Natural Products and Chinese Medicine; (iii) Metal Anticancer Medicine, Diagnostics and Theranostics; and (iv) Multi-Omics and Innovative Analytical Technologies for Health. Applicants from non-local universities are welcome to apply if the qualification awarding institution is among the top 100 institutions (i.e. in the latest publication of any of the following world university ranking tables: (1) Quacquarelli Symonds World University Rankings, (2) Shanghai Jiao Tong University (Academic Ranking of World Universities), or (3) Times Higher Education World University Rankings). They should have a good research publication record and research experience in at least one of the research areas including catalysis, organic synthesis, bioinorganic chemistry, medicinal chemistry, Chinese medicine, natural products, metal-based therapeutics and diagnostics, bioimaging, mass spectrometry, proteomics, metabolomics, cancer biology and pharmacology, cancer stem cells and animal models of cancers. They should also have the ability to work independently as well as in a team, and be self-motivated. The appointees will participate in the ITC projects and join the Laboratory led by Professor Chi-Ming Che which integrates chemical science and biomedical science for the development of new molecular medicines and diagnostics tools for the treatment and analysis of human diseases with a focus on cancer. They will conduct research on synthetic chemistry, chemical biology, cell biology and drug discovery and work with a multidisciplinary team of chemists and biologists. Working off-campus may be required.

A highly competitive salary commensurate with qualifications and experience will be offered, in addition to annual leave and medical benefits. At current rates, salaries tax does not exceed 15% of gross income.

Applicants should apply online and upload a cover letter, an up-to-date C.V. and 2 reference letters. Review of applications will commence as soon as possible and continue until December 31, 2020, or until the posts are filled, whichever is earlier.

Continue reading here:

Postdoctoral Fellow, Department of Chemistry job with THE UNIVERSITY OF HONG KONG | 213493 - Times Higher Education (THE)

Director Wray Discusses Threat Posed By China to U.S. Economic and National Security | Federal Bureau of Investigation – Federal Bureau of…

Its the people of the United States who are the victims of what amounts to Chinese theft on a scale so massive that it represents one of the largest transfers of wealth in human history.

If you are an American adult, it is more likely than not that China has stolen your personal data.

In 2017, the Chinese military conspired to hack Equifax and made off with the sensitive personal information of 150 million Americanswere talking nearly half of the American population and most American adultsand as Ill discuss in a few moments, this was hardly a standalone incident.

Our data isnt the only thing at stake hereso are our health, our livelihoods, and our security.

Weve now reached the point where the FBI is opening a new China-related counterintelligence case about every 10 hours. Of the nearly 5,000 active FBI counterintelligence cases currently underway across the country, almost half are related to China. And at this very moment, China is working to compromise American health care organizations, pharmaceutical companies, and academic institutions conducting essential COVID-19 research.

But before I go on, let me be clear: This is not about the Chinese people, and its certainly not about Chinese Americans. Every year, the United States welcomes more than 100,000 Chinese students and researchers into this country. For generations, people have journeyed from China to the United States to secure the blessings of liberty for themselves and their familiesand our society is better for their contributions. So, when I speak of the threat from China, I mean the government of China and the Chinese Communist Party.

To understand this threat and how we must act to respond to it, the American people should remember three things.

First: We need to be clear-eyed about the scope of the Chinese governments ambition. Chinathe Chinese Communist Partybelieves it is in a generational fight to surpass our country in economic and technological leadership.

That is sobering enough. But its waging this fight not through legitimate innovation, not through fair and lawful competition, and not by giving their citizens the freedom of thought and speech and creativity that we treasure here in the United States. Instead, China is engaged in a whole-of-state effort to become the worlds only superpower by any means necessary.

The second thing the American people need to understand is that China uses a diverse range of sophisticated techniqueseverything from cyber intrusions to corrupting trusted insiders. Theyve even engaged in outright physical theft. And theyve pioneered an expansive approach to stealing innovation through a wide range of actorsincluding not just Chinese intelligence services but state-owned enterprises, ostensibly private companies, certain kinds of graduate students and researchers, and a whole variety of other actors working on their behalf.

To achieve its goals and surpass America, China recognizes it needs to make leaps in cutting-edge technologies. But the sad fact is that instead of engaging in the hard slog of innovation, China often steals American intellectual property and then uses it to compete against the very American companies it victimizedin effect, cheating twice over. Theyre targeting research on everything from military equipment to wind turbines to rice and corn seeds.

Through its talent recruitment programs, like the so-called Thousand Talents Program, the Chinese government tries to entice scientists to secretly bring our knowledge and innovation back to Chinaeven if that means stealing proprietary information or violating our export controls and conflict-of-interest rules.

Take the case of scientist Hongjin Tan, for example, a Chinese national and American lawful permanent resident. He applied to Chinas Thousand Talents Program and stole more than $1 billionthats with a bworth of trade secrets from his former employer, an Oklahoma-based petroleum company, and got caught. A few months ago, he was convicted and sent to prison.

Or theres the case of Shan Shi, a Texas-based scientist, also sentenced to prison earlier this year. Shi stole trade secrets regarding syntactic foam, an important naval technology used in submarines. Shi, too, had applied to Chinas Thousand Talents Program, and specifically pledged to digest and absorb the relevant technology in the United States. He did this on behalf of Chinese state-owned enterprises, which ultimately planned to put the American company out of business and take over the market.

In one of the more galling and egregious aspects of the scheme, the conspirators actually patented in China the very manufacturing process theyd stolen, and then offered their victim American company a joint venture using its own stolen technology. Were talking about an American company that spent years and millions of dollars developing that technology, and China couldnt replicate itso, instead, it paid to have it stolen.

And just two weeks ago, Hao Zhang was convicted of economic espionage, theft of trade secrets, and conspiracy for stealing proprietary information about wireless devices from two U.S. companies. One of those companies had spent over 20 years developing the technology Zhang stole.

These cases were among more than a thousand investigations the FBI has into Chinas actual and attempted theft of American technologywhich is to say nothing of over a thousand more ongoing counterintelligence investigations of other kinds related to China. Were conducting these kinds of investigations in all 56 of our field offices. And over the past decade, weve seen economic espionage cases with a link to China increase by approximately 1,300 percent.

The stakes could not be higher, and the potential economic harm to American businesses and the economy as a whole almost defies calculation.

As National Security Advisor OBrien discussed in his June remarks, the Chinese government is also making liberal use of hacking to steal our corporate and personal dataand theyre using both military and non-state hackers to do it. The Equifax intrusion I mentioned just a few moments ago, which led to the indictment of Chinese military personnel, was hardly the only time China stole the sensitive personal information of huge numbers of the American public.

For example, did any of you have health insurance through Anthem or one of its associated insurers? In 2015, Chinas hackers stole the personal data of 80 million of that companys current and former customers.

Or maybe youre a federal employeeor you used to be one, or you applied for a government job once, or a family member or roommate did. Well, in 2014, Chinas hackers stole more than 21 million records from OPM, the federal governments Office of Personnel Management.

Why are they doing this? First, China has made becoming an artificial intelligence world leader a priority, and these kinds of thefts feed right into Chinas development of artificial intelligence tools.

Compounding the threat, the data China stole is of obvious value as they attempt to identify people for secret intelligence gathering. On that front, China is using social media platformsthe same ones Americans use to stay connected or find jobsto identify people with access to our governments sensitive information and then target those people to try to steal it.

Just to pick one example, a Chinese intelligence officer posing as a headhunter on a popular social media platform recently offered an American citizen a sizeable sum of money in exchange for so-called consulting services. That sounds benign enough until you realize those consulting services were related to sensitive information the American target had access to as a U.S. military intelligence specialist.

Now that particular tale has a happy ending: The American citizen did the right thing and reported the suspicious contact, and the FBI, working together with our armed forces, took it from there. I wish I could say that all such incidents ended that way.

Its a troublingly similar story in academia.

Through talent recruitment programs like the Thousand Talents Program I mentioned just a few moments ago, China pays scientists at American universities to secretly bring our knowledge and innovation back to Chinaincluding valuable, federally funded research. To put it bluntly, this means American taxpayers are effectively footing the bill for Chinas own technological development. China then leverages its ill-gotten gains to undercut U.S. research institutions and companies, blunting our nations advancement and costing American jobs. And we are seeing more and more of these cases.

In May alone, we arrested both Qing Wang, a former researcher with the Cleveland Clinic who worked on molecular medicine and the genetics of cardiovascular disease, and Simon Saw-Teong Ang, a University of Arkansas scientist doing research for NASA. Both of these guys were allegedly committing fraud by concealing their participation in Chinese talent recruitment programs while accepting millions of dollars in American federal grant funding.

That same month, former Emory University professor Xiao-Jiang Li pled guilty to filing a false tax return for failing to report the income hed received through Chinas Thousand Talents Program. Our investigation found that while Li was researching Huntingtons disease at Emory, he was also pocketing half a million unreported dollars from China.

In a similar vein, Charles Lieber, chair of Harvards Department of Chemistry and Chemical Biology, was indicted just last month for making false statements to federal authorities about his Thousand Talents participation. The United States has alleged that Lieber concealed from both Harvard and the NIH his position as a strategic scientist at a Chinese universityand the fact that the Chinese government was paying him, through the Wuhan Institute of Technology, a $50,000 monthly stipend, more than $150,000 in living expenses, and more than $1.5 million to establish a laboratory back in China.

Theres more. Another tool China and the Chinese Communist Party use to manipulate Americans is what we call malign foreign influence.

Now, traditional foreign influence is a normal, legal diplomatic activity typically conducted through diplomatic channels. But malign foreign influence efforts are subversive, undeclared, criminal, or coercive attempts to sway our governments policies, distort our countrys public discourse, and undermine confidence in our democratic processes and values.

China is engaged in a highly sophisticated malign foreign influence campaign, and its methods include bribery, blackmail, and covert deals. Chinese diplomats also use both open, naked economic pressure and seemingly independent middlemen to push Chinas preferences on American officials.

Just take one all-too-common illustration: Lets say China gets wind that some American official is planning to travel to Taiwanthink a governor, a state senator, a member of Congress. China does not want that to happen, because that travel might appear to legitimize Taiwanese independence from Chinaand legitimizing Taiwan would, of course, be contrary to Chinas One China policy.

So what does China do? Well, China has leverage over the American officials constituentsAmerican companies, academics, and members of the media all have legitimate and understandable reasons to want access to Chinese partners and markets. And because of the authoritarian nature of the Chinese Communist Party, China has immense power over those same partners and markets. So, China will sometimes start by trying to influence the American official overtly and directly. China might openly warn that if the American official goes ahead and takes that trip to Taiwan, China will take it out on a company from that officials home state by withholding the companys license to manufacture in China. That could be economically ruinous for the company, would directly pressure the American official to alter his travel plans, and the official would know that China was trying to influence him.

That would be bad enough. But the Chinese Communist Party often doesnt stop there; it cant stop there if it wants to stay in powerso it uses its leverage even more perniciously. If Chinas more direct, overt influence campaign doesnt do the trick, they sometimes turn to indirect, covert, deceptive influence efforts.

To continue with the illustration of the American official with travel plans that the Chinese Communist Party doesnt like, China will work relentlessly to identify the people closest to that officialthe people that official trusts most. China will then work to influence those people to act on Chinas behalf as middlemen to influence the official. The co-opted middlemen may then whisper in the officials ear and try to sway the officials travel plans or public positions on Chinese policy. These intermediaries, of course, arent telling the American official that theyre Chinese Communist Party pawnsand worse still, some of these intermediaries may not even realize theyre being used as pawns, because they, too, have been deceived.

Ultimately, China doesnt hesitate to use smoke, mirrors, and misdirection to influence Americans.

Similarly, China often pushes academics and journalists to self-censor if they want to travel into China. And weve seen the Chinese Communist Party pressure American media and sporting giants to ignore or suppress criticism of Chinas ambitions regarding Hong Kong or Taiwan. This kind of thing is happening over and over, across the United States.

And I will note that the pandemic has unfortunately not stopped any of thisin fact, we have heard from federal, state, and even local officials that Chinese diplomats are aggressively urging support for Chinas handling of the COVID-19 crisis. Yes, this is happening at both the federal and state levels. Not that long ago, we had a state senator who was recently even asked to introduce a resolution supporting Chinas response to the pandemic.

The punchline is this: All of these seemingly inconsequential pressures add up to a policymaking environment in which Americans find themselves held over a barrel by the Chinese Communist Party.

All the while, Chinas government and Communist Party have brazenly violated well-settled norms and the rule of law.

Since 2014, Chinese General Secretary Xi Jinping has spearheaded a program known as Fox Hunt. Now, China describes Fox Hunt as some kind of international anti-corruption campaignit is not. Instead, Fox Hunt is a sweeping bid by General Secretary Xi to target Chinese nationals whom he sees as threats and who live outside China, across the world. Were talking about political rivals, dissidents, and critics seeking to expose Chinas extensive human rights violations.

Hundreds of the Fox Hunt victims that they target live right here in the United States, and many are American citizens or green card holders. The Chinese government wants to force them to return to China, and Chinas tactics to accomplish that are shocking. For example, when it couldnt locate one Fox Hunt target, the Chinese government sent an emissary to visit the targets family here in the United States. The message they said to pass on? The target had two options: return to China promptly, or commit suicide. And what happens when Fox Hunt targets refuse to return to China? In the past, their family members both here in the United States and in China have been threatened and coerced, and those back in China have even been arrested for leverage.

Ill take this opportunity to note that if you believe the Chinese government is targeting youthat youre a potential Fox Hunt victimplease reach out to your local FBI field office.

Understanding how a nation could engage in these tactics brings me to the third thing the American people need to remember: that China has a fundamentally different system than oursand its doing all it can to exploit the openness of ours while taking advantage of its own closed system.

Many of the distinctions that mean a lot here in the United States are blurry or almost nonexistent in ChinaI'm talking about distinctions between the government and the Chinese Communist Party, between the civilian and military sectors, and between the state and the private sector.

For one thing, an awful lot of large Chinese businesses are state-owned enterprisesliterally owned by the government, and thus the Party. And even if they arent, Chinas laws allow its government to compel any Chinese company to provide any information it requestsincluding American citizens data.

On top of that, Chinese companies of any real size are legally required to have Communist Party cells inside them to keep them in line. Even more alarmingly, Communist Party cells have reportedly been established in some American companies operating in China as a cost of doing business there.

These kinds of features should give U.S. companies pause when they consider working with Chinese corporations like Huaweiand should give all Americans pause, too, when relying on such a companys devices and networks. As the worlds largest telecommunications equipment manufacturer, Huawei has broad access to much that American companies do in China. Its also been charged in the United States with racketeering conspiracy and has, as alleged in the indictment, repeatedly stolen intellectual property from U.S. companies, obstructed justice, and lied to the U.S. government and its commercial partners, including banks.

The allegations are clear: Huawei is a serial intellectual property thief, with a pattern and practice of disregarding both the rule of law and the rights of its victims. I have to tell you, it certainly caught my attention to read a recent article describing the words of Huaweis founder, Ren Zhengfei, about the companys mindset. At a Huawei research and development center, he reportedly told employees that to ensure the companys survival, they need toand I quotesurge forward, killing as you go, to blaze us a trail of blood. Hes also reportedly told employees that Huawei has entered, to quote, a state of war. I certainly hope he couldnt have meant that literally, but its hardly an encouraging tone, given the companys repeated criminal behavior.

In our modern world, there is perhaps no more ominous prospect than a hostile foreign governments ability to compromise our countrys infrastructure and devices. If Chinese companies like Huawei are given unfettered access to our telecommunications infrastructure, they could collect any of your information that traverses their devices or networks. Worse still: Theyd have no choice but to hand it over to the Chinese government if askedthe privacy and due process protections that are sacrosanct in the United States are simply non-existent in China.

The Chinese government is engaged in a broad, diverse campaign of theft and malign influence, and it can execute that campaign with authoritarian efficiency. Theyre calculating. Theyre persistent. Theyre patient. And theyre not subject to the righteous constraints of an open, democratic society or the rule of law.

China, as led by the Chinese Communist Party, is going to continue to try to misappropriate our ideas, influence our policymakers, manipulate our public opinion, and steal our data. They will use an all-tools and all-sectors approachand that demands our own all-tools and all-sectors approach in response.

Our folks at the FBI are working their tails off every day to protect our nations companies, our universities, our computer networks, and our ideas and innovation. To do that, were using a broad set of techniquesfrom our traditional law enforcement authorities to our intelligence capabilities.

And I will briefly note that were having real success. With the help of our many foreign partners, weve arrested targets all over the globe. Our investigations and the resulting prosecutions have exposed the tradecraft and techniques the Chinese use, raising awareness of the threat and our industries defenses. They also show our resolve and our ability to attribute these crimes to those responsible. Its one thing to make assertionsbut in our justice system, when a person, or a corporation, is investigated and then charged with a crime, we have to prove the truth of the allegation beyond a reasonable doubt. The truth mattersand so, these criminal indictments matter. And weve seen how our criminal indictments have rallied other nations to our causewhich is crucial to persuading the Chinese government to change its behavior.

Were also working more closely than ever with partner agencies here in the U.S. and our partners abroad. We cant do it on our own; we need a whole-of-society response. Thats why we in the intelligence and law enforcement communities are working harder than ever to give companies, universities, and the American people themselves the information they need to make their own informed decisions and protect their most valuable assets.

Confronting this threat effectively does not mean we shouldnt do business with the Chinese. It does not mean we shouldnt host Chinese visitors. It does not mean we shouldnt welcome Chinese students or coexist with China on the world stage. But it does mean that when China violates our criminal laws and international norms, we are not going to tolerate it, much less enable it. The FBI and our partners throughout the U.S. government will hold China accountable and protect our nations innovation, ideas, and way of lifewith the help and vigilance of the American people.

Thank you for having me here today.

View original post here:

Director Wray Discusses Threat Posed By China to U.S. Economic and National Security | Federal Bureau of Investigation - Federal Bureau of...

This Ancient Sea Creature Builds Its Body With a Whisper, not a Scream – The New York Times

Building a body from scratch is a daunting task, one that requires careful coordination among all those involved. Thats why natures starting stuff cells have learned to be remarkably chatty to get the job done right.

Decades of experiments on embryos from fish, frogs and mice have painted a general picture of the way these cellular conversations often go. Cells will emit molecular signals that can diffuse deep into their environment, not unlike messages broadcast over radio waves. Such widely transmitted messages, which direct information to distant anatomical locales, have long been considered essential to the act of building a body.

It is what is discussed in textbooks, said Lo Guignard, a biologist at the Max Delbrck Center for Molecular Medicine in Berlin.

But nature has developed subtler ways of sending messages, too.

By eavesdropping on the embryos of sea squirts, saclike filter feeders that inhabit the worlds shallow ocean floors, Dr. Guignard and his colleagues may have identified another way that burgeoning cells correspond. During their earliest days, sea squirt cells seem to exchange signals only with their nearest neighbors, rather than dispatching signals to cells that are farther afield, according to a paper published Thursday in Science.

Its the microscopic equivalent of passing notes between close friends a talking tactic that may be more limited in reach than its long-range counterpart, but could allow for the delivery of especially precise instructions.

Most researchers in the field of developmental biology have never really thought about cell signaling in this way, said Chen Cao, who researches sea squirt development at Princeton University but wasnt involved in the new study. This is a brand-new angle on how embryo cells find their fates, she said.

Sea squirts are more closely related to vertebrates animals like humans with backbones than you might expect from brainless blobs. And the embryos of some sea squirt species, such as Phallusia mammillata, are completely transparent, making them especially easy to observe.

The researchers used a highly sensitive form of microscopy to track 10 Phallusia mammillata embryos during six hours of their early development. Snapping images every two minutes, the cameras recorded the position and shape of each cell in the embryo through multiple rounds of division, until the sea squirts-to-be each contained several hundred cells apiece, about a third of the way through development.

Unlike frog or mouse embryo cells which may zip to and fro during development, young sea squirt cells stayed mostly in place. Mathematical modeling also showed that the cells signaled only to the cells they touched, almost like they were whispering to one another. In at least these early stages of development, sea squirt cells didnt seem to need long-distance chatter.

The findings raise the possibility that you can be a whole, sophisticated embryo by way of local signals alone, said Patrick Lemaire, a developmental biologist at the University of Montpellier in France and a co-author of the study.

Remarkably, these patterns repeated themselves in all the sea squirts the team observed, to the point where the same cells occupied nearly identical neighborhoods in different embryos. Dr. Lemaire said he thinks this rigid consistency may have played some role in keeping the squishy forms of sea squirts mostly unchanged since they first appeared on the planet hundreds of millions of years ago.

This is a beautiful piece of work, said Cassandra Extavour, a developmental biologist at Harvard University who wasnt involved in the study. And though sea squirts are the only creatures in which these developmental patterns have been rigorously documented so far, Dr. Extavour said she expects there will be many, many more animals that rely on a signaling principle like the one outlined here.

Different types of signaling also arent mutually exclusive. Dr. Cao said she thinks even sea squirt cells might make some long-distance calls later in development.

Scientists have long looked for a unifying view of how cell-cell communication works across animals, said Didem Sarikaya, a developmental biologist at the University of California, Davis, who wasnt involved in the study. But its becoming increasingly clear that is not the case, Dr. Sarikaya said.

We tend to observe the things we have already known about before, Dr. Extavour said. But if we understand this lens is very narrow, we might not be surprised by findings like this.

Link:

This Ancient Sea Creature Builds Its Body With a Whisper, not a Scream - The New York Times

NantHealth Points To The Future Of Healthcare – Seeking Alpha

MantHealth (NH) offers cancer molecular profiling solutions that enable personalization in a number of cancer treatments. This business, which has been lingering for a couple of years has received an important FDA approval which makes approval for Medicare and Medicaid use very likely. This, together with the sale of their Connected Care business has boosted the stock price significantly, but we think it's not too late to step on board.

The company is also is enabling a more integrated and data-driven healthcare solution through its two SaaS platforms, which are growing and account for most of the company's revenues to date.

These proven integration solutions are offered to an industry, which as they claim (and, dare we say, not without reason) suffers from a host of unnecessary complexity and inefficiencies, most notably:

Because of these inhibitions, the healthcare system is struggling to make the shift towards a more holistic, data-driven approach, the culmination of which is individualized medicine.

Personalized medicine is based on personalized data that is increasingly becoming available through advances in molecular medicine and real-time biometrics (remote monitoring devices and the like).

These solutions, like the company's own GPS business, generate a veritable deluge of data which, for a coordinated and individualized approach need to be collected, analyzed and distributed, and it's here where the company's SaaS solutions intervene and add value. We'll quickly introduce the company's solutions below.

From the 10-K:

GPS Cancer is a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing, providing oncologists with insights into the unique molecular signature of a patients cancer to inform personalized treatment strategies.

What GPS Cancer does is comparing the patient's whole genome/exome sequencing of a persons tumor sample with their normal sample in order to highlight molecular alterations that are specific to their tumor DNA.

These alterations are then subsequently confirmed by RNA sequencing. All this enables the matching of these alterations with drugs that might be effective against tumors containing the specific change. And these solutions are constantly fine-tuned by machine learning.

This is the company's blood based test that allows non-invasive profiling of tumors and monitoring quantitative response to treatment, from the 10-K:

Liquid GPS looks beyond cfDNA to cfRNA, which allows profiling and trending of actionable biomarkers that cannot be assessed through cfDNA alone. In addition to providing molecular insight into key guidelines-based biomarkers (e.g., EGFR, ALK, ROS1, KRAS), this powerful RNA-based approach enables a variety of capabilities and applications not typically available from a liquid biopsy test.

It is able to monitor targeted therapies, immunotherapy and chemotherapy responses.

This is the company's SaaS based decision support system which provides evidence-based clinical decision support for physicians who are threatened to be overwhelmed by today's rapid advancements in molecular and biometric medicine.

Eviti centralizes stuff like clinical content, treatment cost from Medicare reimbursements and treatment toxicity data. It has access to over 7600 clinical trials and 4000+ evidence-based treatment regimes.

NaviNet Open is a payer-provider workflow collaboration platform in order to increase efficiency, lower cost, improve provider satisfaction and enable communication between health plans and providers.

The company sold its Connected Care business for $47M in February to Masimo (MASI), exiting DCX, VCX, HBox and Shuttle Cable. The Connected Care business generated $1.2M in sales in Q1, a small part of overall revenue ($23M).

While operational performance has improved, the company hasn't been able to grow much in the past four years:

Data by YCharts

After the sale of its Connected Care business, the company has two revenue categories:

To date, the company's SaaS revenue generates most of its revenue but it does gain some revenue from sequencing and molecular analysis. However, last quarter saw a big decline to just $59K (down from $814K a year ago).

The stagnant revenue in part is just appearance as the company's SaaS business has been growing, from $60.7M in 2017 to $65.6M in 2018 to $72.8M in 2019, because the company de-emphasized its GPS business as costs were outweighing revenues. The company keeps on adding new customers (like here and here) to its SaaS businesses, a few were mentioned on the Q1CC.

The company keeps improving their products and adding new Eviti and NaviNet features.

For this business to take off, the wait is basically for a positive coverage determination from CMS, from the Q1CC:

we expect to continue to see minimal sequencing and molecular analysis revenue impact until we receive a positive coverage determination from CMS.

However, that event seems near, from the 10-K (our emphasis):

In the fourth quarter of 2019, we received FDA 510(K) authorization for Omics Core, the nations first FDA authorized whole exome tumor-normal in vitro diagnostic (IVD) that measures overall tumor mutational burden (TMB) in cancer tissue, completing a key step towards achieving Medicare coverage.

Which, together with the sale of the Connected Care business, explains the rally in the shares, from FinViz:

It's GPS business generated $2.55M in revenues in 2017, $3.13M in 2018 and $1.73M in 2019. Here too, apart from the FDA approval for Omics Core, there are other developments and improvements.

The company launched a new AI platform which can automatically distinguish sub-types lung cancer pathology and improves on that ability, from PR:

Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.

Accurately identifying and quantifying tumor-infiltrating white cells is extremely important for prognosis and treatment decisions in this era of personalized medicine, yet it currently requires manual review of whole slide images by medically trained pathologists, and incurs significant delays and cost, explains Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth.

And they are working on a similar solution for breast cancer. In principle, their TMB (tumor mutational burden) test capability is a generic capability with wide application scope, here is a description of the mechanics from company PR:

Omics Core reports a cancer patient's overall TMB by sequencing and comparing 19,396 protein-coding genes targeting 39 million base pairs of the human genome from a tumor sample and a normal sample, typically from blood or mucosal membrane. TMB indicates the sum of all acquired gene-coding mutations in a tumor genome and is increasingly used to predict response to therapy and identify tumors that could benefit from immunotherapy. In addition, the test reports somatic mutations in 468 cancer-relevant genes accurate to 2% allele frequency, to inform clinical decisions about patient treatment. "Tumor mutation burden ... is now recognized as a key biomarker across multiple tumor types," said Patrick Soon-Shiong, chairman and CEO of Nanthealth. "Studies have shown that immunotherapy treated with high TMB had better outcomes compared to those with low TMB."

And here is a description of a peer reviewed article how this improves targeting capabilities of treatments. It's the more general applicability of TMB and the FDA approval that shareholders are rejoicing.

According to management, two things stand out (PR, our emphasis):

Nanthealth is positioning its tumor-normal test as an advancement over competitors like Myriad Genetics Inc., Color Genomics Inc. and Invitae Corp., which have limited gene panels to look at hereditary risk. By sequencing the whole exome, "we have the ability to identify things that others are missing, and that's particularly critical for drug development," Sandeep Reddy, Nanthealth's chief medical officer, told BioWorld MedTech. "We know about maybe cancer risk, but what do we know about autism or Alzheimer's? By getting that information, that becomes transformative."

As described in that PR, the company's TMB test spots things that other solutions don't, resulting in a more personalized approach to what therapies might be more successful, and it has applicability beyond screening for cancers.

But from a financial point of view, things are also going pretty well.

Data by YCharts

GAAP margins have been trending up and gross margin was much better than a year ago (60% versus 49%), up on product mix (the shift towards its SaaS business).

Operating expenses declined from $20.2M in Q1 2019 to $16.8M in Q1 2020, but $1.1M of that decline is related to the sold Connected Care business.

While cash flow is still negative, there has been tremendous improvement in the last 2.5 years.

Data by YCharts

The net cash burn in Q1 was still around $5M, but this included various closing costs and other front-end loaded costs in relation to the sale of the Connected Care business.

And with that sale the balance sheet has improved a lot, with the company having $47.5M in cash on the books, although the company does have a substantial $95.3M in long-term debt, from the 10-Q:

Data by YCharts

The valuation has jumped along with the share price recently but we think it's still not excessive, it has been much higher in the past on a much more distant promise of monetizing their TMB solutions and in the meantime the company developed a successful SaaS business with their Eviti and NaviNet platforms.

With a backwards looking EV/S of 8X for a company with a unique product that is about to get monetized and a successful SaaS business is high, but not overly so. Analyst still expect EPS losses, $0.23 this year falling to -$0.18 next year, but the company doesn't burn much cash and has plenty of it.

While much is uncertain about the potential of the company's GPS business and the economics of it, the company does have unique capabilities that are likely to become important tools in fighting a number of cancers and the underlying capabilities seem to have wide applicability.

Add to that an attractive SaaS business a declining cash burn and the sale of its Connected Care business providing enough cash to keep the company going for the foreseeable future, and we think we still have an attractive proposition for shareholders, even if it looks like the shares might want to have to digest recent strong gains.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Continued here:

NantHealth Points To The Future Of Healthcare - Seeking Alpha

Peer-reviewed JNU study among 2 that link BCG & Covid again, but some experts not convinced – ThePrint

Text Size:A- A+

Bengaluru: Two studies released this week, one led by Indian researchers from JNU, brought back a theory that first emerged in the early days of the pandemic that BCG vaccination may be linked to reduced Covid-19 transmission and mortality.

One of them, published in the journal Cell Death and Disease on 8 July, was carried out by an international team of researchers. It was led by researchers from the JNU School of Computer and System Sciences, in collaboration with colleagues from the universitys Special Centre for Molecular Medicine and School of Computational and Integrative Sciences, besides those from Italy, China and the US.

The second study, published in PNAS on 9 July, was carried out by American researchers.

The first study involved an assessment of a possible correlation between Covid-19 incidence and mortality with the BCG vaccine, which is primarily targeted at tuberculosis. It also sought to examine the preventive use of chloroquine, an antimalarial drug that has been touted as a potential coronavirus prophylactic and treatment.

While it found a potential correlation between a nations BCG policy and lowered disease incidence/mortality, it failed to find a statistically significant correlation with chloroquine.

The American study also found a potential correlation between BCG vaccination rates and Covid mortality, but the authors suggested further research into the subject.

Both journals are peer-reviewed, but PNAS allows authors to pick reviewers. The studies were both observational assessments based on existing data and not based on clinical trials. The authors themselves acknowledge certain limitations and experts have called for more research before a conclusive link can be proved.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrints future.

SUBSCRIBE NOW

Also Read: Can BCG vaccine protect against Covid-19? Heres why the excitement needs to be tempered

The BCG vaccine has been in use since 1921, but works only for an average of 60 per cent of the population. Its use has reduced drastically after decades of vaccination drives the world over, including in the Indian subcontinent.

Today, it is proving inefficient against lung TB, the most common form of the disease in India, but there are studies underway to find a replacement.

But there is some evidence that BCG offers protection to some unrelated viruses like influenza.

The Cell authors classified countries into three groups on the basis of their BCG policy: Countries that never adopted universal BCG vaccination, ones that did but subsequently discontinued it, and ones that currently exercise it.

The authors reportedly found that the number of cases across different age groups was always higher for countries without a BCG policy. For adults aged over 45, vaccinated groups had significantly lower case rates. Vaccination rates did not seem to matter in children under 15 since disease incidence in this group was found to be low.

The PNAS study, too, noted that countries with no vaccination policy had a higher rate of deaths than those that did. Both studies claim that the case load was marginally lower even in countries with interrupted or irregular BCG drives.

The Cell team further speculates that the type of BCG vaccine strain used also plays a role, citing high prevalence despite vaccination in Brazil and Russia.

Many countries, including Germany, the Netherlands, Australia, and the US, have initiated trials of BCG vaccines aimed at controlling Covid-19. Immunologist Gobardhan Das, who participated in the Cell study, claims to be working on developing a revamped BCG vaccine for Covid-19.

Also Read: We need to take a break from real-time updates on the Covid vaccine trials. BCG is a far cry

Many observational studies have suggested a link between BCG and Covid-19, but experts in immunology and BCG have called for more research.

It is true that India has had several decades of safe experience with BCG, which has a proven safety record, is inexpensive, and easily available, said Dr S.P. Kalantri, an epidemiologist and medical superintendent at Kasturba Hospital in Wardha, Maharashtra. But using only observational ecological studies to find a pattern with BCG is problematic.

Ecological studies are observational assessments where existing data is analysed, retrospectively, based on geography, and conclusions drawn from them usually form the basis for further studies.

Intuitively, it seems natural that there is a cause and effect relationship, but what holds true for a country does not hold true for communities or individuals, Kalantri said. In epidemiology, he added, this is called an ecological fallacy.

Kalantri said there are other factors that could contribute to Covid-19 data being the way it is, the most important of which is the average age of the population. The average age of most BCG countries, he added, is lower than that of non-BCG nations.

We know that incidence and mortality is age-specific. As age advances, prevalence and mortality also goes up. In the face of such factors, we shouldnt fall into the trap of concluding that the disease pattern is because of BCGs effects, he added. We need proper randomised controlled trials to show statistical significance, he said.

Said Madhukar Pai, epidemiologist at McGill University, Canada, Several countries now have rapidly escalating Covid-19 outbreaks, including Brazil, India, Russia, Mexico, Peru, Chile. And they all routinely give BCG at birth. So, it is dangerous to make conclusions in such a dynamic situation. We simply cannot act on these ecologic correlations and must wait for randomised trials on BCG and Covid-19.

The study authors also noted their own limitations.

The Cell study only included data from middle- and high-income countries.

The PNAS study stated that the data is difficult to review because of broad differences between countries in socioeconomic status, demographic structure, rural vs urban settings, time of arrival of the pandemic, number of tests and criteria, etc.

Also Read: Why the fight over a coronavirus vaccine will be intense, irrational and even nasty

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And we arent even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrints future. It will take just a few seconds of your time.

Support Our Journalism

Original post:

Peer-reviewed JNU study among 2 that link BCG & Covid again, but some experts not convinced - ThePrint

University of Bristol research investigates the effects of climate change on pollinators and human health – Epigram

By Jade Bruce, Second year, Cellular and Molecular Medicine

Climate change has a global impact. University of Bristol scientists are leading an international team to investigate how climate change may lead to the decline of pollinators and the effect this may have on human.

Spring and summer are the months where blossoming trees line parks, flowers of every colour erupt into full bloom and bees whizz from plant to plant. Although despite being the most well-known bees are not the only pollinators which deserve our recognition. From beetles to bats, an array of pollinators provides a free yet vital service of transporting pollen between plants necessary for fertilization.

Researchers at the University of Bristol have received 1 million from The Belmont Forum to lead and collaborate alongside an international team, investigating the effects of climate change on pollinators, and in turn on human diet and health.

Unpredictable weather patterns, shifting timing of seasons and extreme temperatures associated with climate change, put pollinators under threat. The concerning decline in their populations is currently being observed all around the world. A study carried out by The WWF and Buglife, in the east of England, found that 17 species of bee have already gone regionally extinct.

Indeed, around 90% of the worlds wild plants and of crop species depend primarily on animal-mediated pollination. Pollinators around the globe are key to ensuring that there is nutritious food on our supermarket shelves and in our fridges. This essential service has been placed in jeopardy due to the far-reaching impacts of climate change.

Pollination enables the production of seeds and is an essential process for the reproduction of many different plants. Transfer of pollen can occur through several means, such as by wind and water. However, the most common and efficient pollination method is animal-mediated. Animals pollinate a wide range of plants, including those which produce fruit, vegetables, nuts, and spices.

The decline of pollinators does not only have a destructive effect on biodiversity, but also a major impact on global food production. The term ecological Armageddon has been aptly coined to describe the loss of our pollinators. Pollinator decline is closely correlated to more frequent declines in the crop yields they pollinate.

This is predicted to have negative impacts on human health, as the essential micronutrients which we get from these foods, such as folate and Vitamin A, are thus lacking from our diet. Food insecurity, as well as decreased access to healthy food and subsequently increased food prices, are therefore possible outcomes of pollinator losses due to climate change.

Access to affordable food remains a challenge for the 736 million people worldwide living in extreme poverty. Pollinator decline threatens to exacerbate the existing barriers to sufficient and nutritious diets. The Bristol research team is focussing their investigations on Nepal, where many already suffer from severe micronutrient deficiencies.

Developing countries, have a greater reliance on the micronutrients found in pollinator-dependent crops, and less access to foods or supplements that could replace these lost. Hence, as seen across many global issues, the impact of pollinator loss is not felt equally certain countries will be disproportionately harmed.

Loss of pollinators could also result in rising rates of micronutrient malnutrition and maybe unexpectedly obesity. This is likely due to the fact that people are forced to turn to cheap, high energy, but less nutritious staple foods. The decline of insect pollinators is representative of the wider decline of biodiversity due to human behaviour.

The worlds climate is our natural life-support system, which provides us with dependable ecosystem services. Climate change and public health are not mutually exclusive: a climate crisis is a public health crisis.

What can one do to tackle this crisis? Jane Memmott, Professor of Ecology at the University of Bristol School of Biological Sciences, said: Climate change is a critical global issue that is already affecting pollinators but, at a local level, pollinator declines can be reversed. Additionally, if the effect of climate change on pollinators is understood, habitat management can be used to mitigate against its effects.

More locally, we can restore the damaged habitats of pollinators and attract them back into gardens and cities by planting pollen-rich flowers, providing water and creating nest sites for wild pollinators.

Some food for thought: maybe next time you see a bee buzzing by, dont swat it away in fear instead, thank it for doing such an almighty job.

Featured: Frank Lammel / UN Women / Asif A. Ali | flickr

Are you pleased by the University of Bristols efforts into exploring the effects of climate change on pollinators and human health?

Read the original:

University of Bristol research investigates the effects of climate change on pollinators and human health - Epigram

Blood Type And Coronavirus Risk: What You Need To Know – Medical Daily

Recent studies claimed that blood types can either help block COVID-19 or increase the risk of getting the disease and its complications. The findings provided hope to many people but health experts warned it may be too early to put our guards down.

Majority of those studies found that people with Type O blood are less likely to catch the novel coronavirus, while those with Type A are more vulnerable. Experts fear that the findings would give people a false sense of security and encourage them to stop following common safety measures, such as wearing masks and social distancing.

In one study in Europe, researchers found that Type A blood increases risk of severe COVID-19 cases by 45 percent. They said people with this blood type are more likely to require oxygen support or a ventilator because of the disease.

Meanwhile, the Type O blood group appeared with 35 percent lower risk. The study analyzed the blood and conditions of 1,610 patients with severe COVID-19 and 2,205 healthy participants.

Other studies in China and New York also provided the same findings in favor of people with Type O blood. However, the possible influence of blood type on COVID-19 appears small compared with other risk factors, such as age and underlying health condition, according to Aaron Glatt, chair of medicine and chief of infectious diseases at Mount Sinai South Nassau in New York.

People with Type O blood "certainly shouldn't walk around high-fiving and saying, I can do whatever I want, I don't have to mask, I don't have to worry about anything because I have O," Glatt, who is also a spokesperson for the Infectious Diseases Society of America, said. "And they shouldn't crawl into a corner of the world and not let anyone near them because they have A. Everybody should practice exactly the same way, whatever your blood type is, in terms of appropriate masking and social distancing."

The studies also did not suggest that Type O people are completely safe from the serious complications of COVID-19. Researchers said they can still get very sick because of the coronavirus infection.

"They have a decreased risk to get infected and to develop severe disease," Andre Franke, author of the European study and professor of molecular medicine at the University of Kiel in Germany, told NBC News. "However, this is only a relative risk reduction, i.e. there is no full protection. Among our patients who died there were also many with blood group O."

A researcher collects blood samples in an unknown laboratory. Pixabay

Continue reading here:

Blood Type And Coronavirus Risk: What You Need To Know - Medical Daily

Fine-tuning brain activity reverses memory problems in mice with autism mutation – Spectrum

Social circuitry: Mice with an autism-linked mutation have better social memory after treatment that calms a related neural circuit.

Georgejason / iStock

Dampening overactive brain circuits alleviates social and spatial memory problems in a mouse model of 22q11.2 deletion syndrome, according to a new study1. The findings hint at the possibility of novel treatments for some difficulties associated with the syndrome.

Deletions of DNA in a chromosomal region known as 22q11.2 often cause intellectual disability or other cognitive difficulties, as well as psychiatric conditions such as schizophrenia. About 16 percent of people with the deletion also have autism2.

The type and severity of traits vary from person to person, in part because the deletion can span roughly 20 to 50 genes. That range makes it difficult to design targeted therapies. And many people with deletions in 22q11.2 are prone to drug-related side effects, such as seizures.

Side effects with drug treatment is one of the hardest parts of dealing with mental illness, says Julia Kahn, a postdoctoral researcher at the Childrens Hospital of Philadelphia in Pennsylvania, who worked on the study. Being able to circumvent that in a very directed manner would be really life-changing for a lot of people.

The study identifies the neural circuits responsible for select behaviors in model mice and shows that manipulating those circuits could offer a new treatment strategy.

It suggests that therapies can be symptom specific, says lead investigator Douglas Coulter, professor of pediatrics and neuroscience at the University of Pennsylvania in Philadelphia.

Coulter and his colleagues manipulated circuits in two regions of the hippocampus in 22q11.2 model mice: the ventral region, which governs social memory, and the dorsal region, involved in spatial memory. They focused on the hippocampus because it is important to social cognition in both mice and people, and previous studies have shown it is unusually small in people with 22q11.2 deletions3.

Before the manipulation, mice missing 22q11.2 perform worse than controls on tests of their social and spatial memory, the study shows. The mice do not distinguish between a new mouse and one they have already met, and they have trouble recognizing when an object in their cage has been moved. Brain imaging also showed that the model mice have overactive neurons in the hippocampus.

The team used a method known as chemogenetics to dampen this overactivity. They gave the mice an injection that prompts some neurons in the hippocampus to produce designer receptors. They then injected the animals with an experimental drug that binds only to those receptors, making the neurons less excitable.

The animals behaviors changed, depending on where they received the injection. Social memory improved when the drug targeted the ventral hippocampus, and spatial memory improved when the drug affected neurons in the dorsal area. Too much inhibition in either area caused the animals memory problems to return.

Using the same technique, the researchers also gave control mice drug-sensitive receptors that either activate or quell the same circuits in the hippocampus. After both treatments, the controls showed the same social memory problems as the mice with 22q11.2 deletions. The results indicate that disrupting the circuits in either direction is enough to change behavior, even without any underlying genetic mutations. The findings were published in May in Biological Psychiatry.

Chemogenetics is a long way off from use in people, but drugs currently on the market may be able to achieve similar outcomes by nudging circuits into a more balanced state, says Peter Scambler, professor of molecular medicine at University College London in England, who was not involved in the work.

Its a proof of principle, he says.

Manipulating circuits that govern specific behaviors should be a goal of all current work at this point, says Anthony LaMantia, professor of developmental disorders and genetics at Virginia Polytechnic Institute and State University in Blacksburg, who was not involved in the work. This is much more targeted and precise. It should make everybody in the field think through how to design their experiments.

Targeting circuits in the hippocampus could help people, because findings in the hippocampus in mice typically translate well to humans, says Rebecca Piskorowski, head of the synaptic plasticity and neuronal circuits team at the Institute of Psychiatry and Neuroscience of Paris in France, who was not involved in the work.

This kind of targeting might also help at any age. The method improved memory in adult mice, suggesting similar treatments could help older people with 22q11.2 deletions and not just children.

This paper shows if you just adjust the activity in a tiny little place, you can somehow compensate for all those developmental problems, Piskorowski says. That is particularly exciting.

Originally posted here:

Fine-tuning brain activity reverses memory problems in mice with autism mutation - Spectrum

Top 25 healthtech influencers to follow on Twitter – Sifted

Healthtech is a hefty sector, spanning digital health, femtech, pharma, AI-assisted diagnostics, drug discovery and plenty more.

It makes money too, and a lot of it. In 2019, global healthtech investment totalled a staggering $7.4bn, with some of Europes healthtech companies landing big funding rounds. Last years biggest European healthtech deal came from London-based unicorn Babylon Health which raised $550m, while this year Stockholm-based digital health startup Kry raised $155m and Paris-based health insurance provider Alan raised $54m.

Theres also a fair few influencers in the healthtech Twittersphere founders, investors and medical professionals who are a goldmine of information opening discussions, sharing resources and educating their followers.

Check out the European healthtech accounts not to miss.

Get the Sifted Newsletter

Thank you for subscribing to the newsletter!

Handle: @joannashields

Who? Shes the chief executive of BenevolentAI, which uses AI to enhance and accelerate scientific discovery, drug discovery and development processes.

Why should you care? The unicorn has shaken the healthtech sector since it was founded in 2013, with the mission to find treatments for the thousands of untreated diseases on our planet. Shields is known for her long and successful career in the tech industry with a focus on using technology to improve humanity, and is leading one of the most ambitious projects to combat diseases including Covid-19.

How about those tweets? If youre looking for updates on finding treatments for Covid-19, insights into AI healthtech and notes on diversity data in healthtech, Shields Twitter feed is the one to keep your eye on.

Handle: @petetrainor

Who? The chief executive of Vala Health, a digital doctor video consultation company.

Why should you care? The digital consultation industry has boomed over the past few months due to Covid-19, and Trainor is in the middle of it all. On top of that, his work as an author takes a uniquely philosophical approach to technology, and he has made a name for himself speaking across the globe on topics such as data and AI. Hes also active in raising awareness about mens mental health and suicide.

How about those tweets? Trainor can be seen opening discussions via Twitter polls on topics such as Covid-19 tracing apps, and is not afraid to (sometimes sarcastically) speak his mind. Definitely an account to follow for those who love to sink their teeth into a debate.

Handle: @MarijaButkovic

Who? Shes the chief executive of Women of Wearables (WoW), an organisation that supports, connects and inspires women who work primarily in wearable tech.

Why should you care? Butkovic is a living library, often writing and blogging on a range of topics from wearable tech, startups and diversity, and is all for helping support female communities in tech. One key ambition at WoW is to show that womens health is not niche by changing perceptions, ending bias and raising awareness.

How about those tweets? Butkovics Twitter feed checks all the boxes for a femtech fanatic. Shes very active in circulating posts and blogs from other women in tech, often about innovations in femtech, and uses her platform to shine light on conversations from webinars and panels she has been on.

Handle: @berci

Who? The director of the Medical Futurist Institute, a research institute with a mission to open discussions about digital health and the future of healthcare.

Why should you care? Mesko is a physician and sci-fi fanatic with a PhD in genomics, and is a prominent keynote speaker known for his engaging and insightful talks on all things digital health. He also stays on top of disruptive trends in medicine, and works with organisations, governments, pharmaceutical and tech companies to take advantage of those.

How about those tweets? Everything under the sun about digital health features on Meskos Twitter feed, from smartphone healthtech tips to portable ultrasound scans and the effect of telemedicine and Covid-19. Look out for his sci-fi book recommendations, or literature relating to healthtech and medicine.

Handle: @ManeeshJuneja

Who? Juneja is a digital health futurist and consultant.

Why should you care? He sees data, and using it correctly, as the key to improving the health of populations through means such as technology. Juneja has unfortunately been battling coronavirus for three months, and has become focused on how we should be using technology to combat the virus. He encourages his followers to think about how health and technology will be affected by the global pandemic.

How about those tweets? Juneja is extremely active on the platform, posting Twitter thread deep dives on his experiences and thoughts while having the virus. These threads cover everything from his symptoms to self isolation tips, and thoughts on how governments and health organisations can handle the outbreak in effective ways.

Handle: @_atanas_

Who? Atanasov is a scientist in molecular medicine and digital health, as well as the editor-in-chief for CRBIOTECH, a biotech journal.

Why should you care? An expert in medicine and a recognised biotech influencer, Atanasov strives to better understand the mechanisms that regulate health and disease and has carried out leading research in areas such as drug discovery.

How about those tweets? Atanasov is a pro at helping his followers understand the complexities of medicine, biotech and digital health, and often calls out new digital health innovations, such as the AI applications that can help healthcare. Also, if you want to learn the latest ins and outs behind very specific topics around Covid-19, like whether youre sick for life after getting the disease, Atanasov has been hot on such posts recently.

Handle: @sophiabendz

Who? Shes a partner at the VC firm Atomico, but will be moving to Cherry Ventures in September this year.

Why should you care? Most people have probably heard Bendz name in the European venture capital and angel investing space. Shes been actively investing in femtech companies for years, including period tracking app Clue and sexual wellness app Ferly.

How about those tweets? Bendz tweets in English and Swedish, and often shares posts on femtech from an investor point of view. Expect to see a lot more on early-stage startups, perhaps in the femtech space, when Bendz joins Cherry Ventures.

Handle: @IlonaKickbusch

Who? She is the director of Kickbusch Health Consult, a global health advisory for organisations, governments and NGOs.

Why should you care? Kickbusch has proven to be quite a big voice in health policy recently, contributing to the agenda for the Health 2020 European policy framework. Shes also concerned about how these policies can leverage healthtech possibilities in the future.

How about those tweets? If you want to look at European health policy through the lens of healthtech, Kickbusch is your go-to. She often posts about the importance of data in health, while starting conversations with her audience, for example, can an AI face mask tracker be effective during the pandemic?

Handle: @health20Paris

Who? Shes the CEO of Basil Strategies, a communications consultancy dedicated to digital health.

Why should you care? Denise is a Paris-based thought leader, with over 20 years experience in digital health. Her company helps clients such as startups, pharmaceutical organisations and hospitals to push forward digital projects. Shes also passionate about the application of virtual reality (VR) in the context of health.

How about those tweets? Youll often find Silber promoting the use of VR as a provider of therapy, recommending insightful articles and podcasts on digital health, so VR lovers should check it out. She tweets in French and English.

Handle: @LionelREICHARDT

Who? He is a consultant for healthtech organisations and a popular healthtech blogger, also known as Pharmageek.

Why should you care? Reichardt has over 15 years of experience in the pharmaceutical industry. While completing his MBA in e-business, he adopted the persona of Pharmageek, gained a large following and has become a respected and influential online speaker on topics such as digital health.

How about those tweets? Whats the next wave of healthcare innovation? Whos leading the latest digital health solutions? What are employers looking for in the healthtech sector right now? Reichardts Twitter feed, primarily in French, covers it all.

Link:

Top 25 healthtech influencers to follow on Twitter - Sifted